Polypharmacy profiles and predictors among adults with autism spectrum disorders

Research in Autism Spectrum Disorders

Volumn 6, Issue 3, 2012, Pages 1142-1149

  Lake, Johanna K ^a,b   Balogh, Robert ^a,b   Lunsky, Yona ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autism spectrum disorder; Medication; Polypharmacy; Psychotropic medication

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; AGGRESSION; ARTICLE; AUTISM; BEHAVIOR; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; POLYPHARMACY; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84859363666     PISSN: 17509467     EISSN: 18780237     Source Type: Journal    
DOI: 10.1016/j.rasd.2012.03.005     Document Type: Article

References (43)

1. Allen, M. H.; Forster, P.; Zealberg, J.; Currier, G. (August, 2002). APA task force on psychiatric emergency services. Report and recommendations regarding psychiatric emergency and crisis services.
2. M.G. Aman, K.S.L. Lam, and A. Collier-Crespin Prevalence and patterns of use of psychoactive medicines among individuals with autism in the autism society of Ohio Journal of Autism and Developmental Disorders 33 2003 527 534
3. M.G. Aman, K.S.L. Lam, and M.E. Van Bourgondien Medication patterns in patients with autism: Temporal, regional, and demographic influences Journal of Child and Adolescent Psychopharmacology 15 2005 116 126
4. M.G. Aman, and K.S. Langworthy Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders Journal of Autism and Developmental Disorders 30 2000 451 459
5. M.G. Aman, C.J. McDougle, L. Scahill, B. Handen, L.E. Arnold, and C. Johnson Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial Journal of the American Academy of Child and Adolescent Psychiatry 48 2009 1143 1154
6. M.G. Aman, M.E. Van Bourgondien, P.L. Wolford, and G. Sarphare Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use Journal of the American Academy of Child and Adolescent Psychiatry 34 1995 1672 1681
7. E. Bradley, and J. Lofchy Learning disability in the accident and emergency department Advances in Psychiatric Treatment 11 2005 345 357
8. M. Broadstock, C. Doughty, and M. Eggleston Systematic review of the effectiveness of pharmacological treatments for adolescents and adults with autism spectrum disorder Autism 11 2007 335 348
9. E.S. Brodkin, C.J. McDougle, S.T. Naylor, D.J. Cohen, and L.H. Price Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation Journal of Child and Adolescent Psychopharmacology 7 1997 109 121
10. T.L. Edwards, E.E. Watkins, A.D. Lotfizadeh, and A. Poling Intervention research to benefit people with autism: How old are the participants? Research in Autism Spectrum Disorders 6 2012 996 999
11. A.J. Esbensen, J.S. Greenberg, M.M. Seltzer, and M.G. Aman A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders Journal of Autism and Developmental Disorders 39 2009 1339 1349
12. A. Hassiotis, D. Robotham, A. Canagasabey, R. Romeo, D. Langridge, and R. Blizard Randomized, single-blind, controlled trial of a specialist behavior therapy team for challenging behavior in adults with intellectual disabilities The American Journal of Psychiatry 166 2009 1278 1285
13. D.A. Hoffman, M. Schiller, J.M. Greenblatt, and D.V. Iosifescu Polypharmacy or medication washout: An old tool revisited Neuropsychiatric Disease and Treatment 7 2011 639 648
14. E. Hollander, A. Phillips, W. Chaplin, K. Zagursky, S. Novotny, and S. Wasserman A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism Neuropsychopharmacology 30 2005 582 589
15. J. Kerbeshian, L. Burd, and K. Avery Pharmacotherapy of autism: A review and clinical approach Journal of Developmental and Physical Disabilities 13 2001 199 228
16. H.W.M. Kwok Psychopharmacology in autism spectrum disorders Current Opinion in Psychiatry 16 2003 529 534
17. K.S. Langworthy-Lam, M.G. Aman, and M.E. Van Bourgondien Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina Journal of Child and Adolescent Psychopharmacology 12 2002 311 321
18. T.J. Lescovec, B.M. Rowles, and R.L. Findling Pharmacological treatment options for autism spectrum disorders in children and adolescents Harvard Review of Psychiatry 16 2008 97 112
19. Y. Lunsky, and J. Elserafi Antipsychotic medication prescription patterns in adults with developmental disabilities who have experienced psychiatric crisis Research in Developmental Disabilities 33 2012 32 38
20. D.S. Mandell, K.H. Morales, S.C. Marcus, A.C. Stahmer, J. Doshi, and D.E. Polsky Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders Pediatrics 121 2008 441 448
21. A. Martin, L. Scahill, A. Klin, and F.R. Volkmar Higher functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use Journal of the American Academy of Child and Adolescent Psychiatry 38 1999 923 931
22. J.L. Matson, and T. Dempsey Autism spectrum disorders: Pharmacotherapy for challenging behaviors Journal of Developmental and Physical Disabilities 20 2008 175 191
23. J.L. Matson, and J.A. Hess Psychotropic drug efficacy and side effects for persons with autism spectrum disorders Research in Autism Spectrum Disorders 5 2011 230 236
24. C.J. McDougle, E.S. Brodkin, S.T. Naylor, D.C. Carlson, D.J. Cohen, and L.H. Price Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation Journal of Clinical Psychopharmacology 18 1998 62 66
25. C.J. McDougle, J.P. Holmes, D.C. Carlson, G.H. Pelton, D.J. Cohen, and L.H. Price A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders Archives of General Psychiatry 55 1998 633 641
26. C.J. McDougle, D.L. Kem, and D.J. Posey Case series: Use of ziprasidone for maladaptive symptoms in youth with autism Journal of the American Academy of Child and Adolescent Psychiatry 41 2002 921 927
27. C.J. McDougle, S.T. Naylor, D.J. Cohen, F.R. Volkmar, G.R. Heninger, and L.H. Price A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder Archives of General Psychiatry 53 1996 1001 1008
28. C.N. Morgan, M. Roy, and P. Chance Psychiatric comorbidity and medication use in autism: A community survey The Psychiatrist 27 2003 378 381
29. S.M. Myers The status of pharmacotherapy for autism spectrum disorders Expert Opinion on Pharmacotherapy 8 2007 1579 1603
30. NASMHPD Medical Directors' Technical Report on Psychiatric Polypharmacy. (September, 2001). National Association of State Mental Health Program Directors Medical Directors Council and Sate Medicaid Directions. http://www.nasmhpd.org/ general-files/publications/med-directors-pubs//Polypharmacy Accessed 05.12.12.
31. National Core Indicators Program. (2009). NCI Annual Summary Report 2008-2009. Available at: http://www.nasddds.org/pdf/2008-2009NCI-Report.pdf
32. D.P. Oswald, and N.A. Sonenklar Medication use among children with autism spectrum disorders Journal of Child and Adolescent Psychopharmacology 17 2007 348 355
33. D.J. Posey, C.A. Erickson, K.A. Stigler, and J. McDougle The use of selective serotonin reuptake inhibitors in autism and related disorders Journal of Child and Adolescent Psychopharmacology 16 2006 181 186
34. D.J. Posey, and J. McDougle The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders Harvard Review of Psychiatry 8 2000 45 63
35. G. Remington, L. Sloman, M. Konstantareas, K. Parker, and R. Gow Clomipramine versus haloperidol in the treatment of autistic disorder: A double-blind placebo-controlled, crossover study Journal of Clinical Psychopharmacology 21 2001 440 444
36. J. Robertson, E. Emerson, N. Gregory, C. Hatton, S. Kessissoglou, and A. Hallam Receipt of psychotropic medication by people with intellectual disability in residential settings Journal of Intellectual Disability Research 44 2000 666 676
37. R.E. Rosenberg, D.S. Mandell, J.E. Farmer, J.K. Law, A.R. Marvin, and P.A. Law Psychotropic medication use among children with autism spectrum disorders enrolled in a National Registry 2007-2008 Journal of Autism Developmental Disorders 40 2010 342 351
38. P.J. Santosh, and G. Baird Pharmacotherapy of target symptoms in autistic spectrum disorders Indian Journal of Pediatrics 68 2001 427 431
39. M.M. Seltzer, P. Shattuck, L. Abbeduto, and J.S. Greenberg Trajectory of development in adolescents and adults with autism Mental Retardation and Developmental Disabilities 10 2004 234 247
40. S. Spreat, J.W. Conroy, and A. Fullerton Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994-2000 American Journal on Mental Retardation 109 2004 322 331
41. E. Tsakanikos, H. Costello, G. Holt, P. Sturmey, and N. Bouras Behaviour management problems are predictors of psychotropic medication and use of psychiatric services in adults with autism Journal of Autism and Developmental Disorders 37 2007 1080 1085
42. A. Witwer, and L. Lecavalier Treatment incidence and patterns in children and adolescents with autism spectrum disorders Journal of Child and Adolescent Psychopharmacology 15 2005 671 681
43. D. Wood, A.G. Hall, J. Zhang, and T. Hou Predictors of psychoactive medication use by persons on the MR/DD home and community based waiver 2006 Florida Center for Medicaid & the Uninsured, College of Public Health and Health Profession, and University of Florida